Journal of Clinical & Experimental Nephrology

Description

Lupus Nephritis (LN) is a severe complication of Systemic Lupus Erythematosus (SLE), a long-term autoimmune disease that predominantly impacts women, particularly those who are of childbearing age. It is a condition marked by inflammation of the kidneys, which can lead to progressive kidney damage if not diagnosed and addressed promptly. This disease is linked with various renal manifestations, such as proteinuria, hematuria, hypertension and renal failure, making it an essential component of SLE management. This article offers an overview of lupus nephritis, concentrating on its pathophysiology, clinical presentation, diagnosis and treatment alternatives [1]. The pathogenesis of lupus nephritis is complex and involves immune dysregulation, in which the body’s immune system attacks its own tissues. In the case of SLE, this leads to the creation of autoantibodies, including Antinuclear Antibodies (ANA), antidsDNA antibodies and other immune complexes that may settle in various organs, including the kidneys. In lupus nephritis, these immune complexes mainly affect the glomeruli, the filtration units of the kidneys. The accumulation of these complexes in the glomerular basement membrane initiates an inflammatory response, which results in glomerular injury [2]. Over time, this inflammatory response can cause glomerulosclerosis, tubulointerstitial fibrosis and ultimately, loss of kidney function. The advancement of LN varies and while some patients experience mild forms of the disease with minimal renal involvement, others may endure rapid kidney deterioration, potentially leading to End-Stage Renal Disease (ESRD) and necessitating dialysis or kidney transplantation [3].

Lupus nephritis

Lupus nephritis can manifest in various ways, ranging from asymptomatic to severe forms with life-threatening complications. The clinical manifestations largely depend on the severity and extent of renal involvement.

Proteinuria: One of the key indicators of lupus nephritis is proteinuria, which indicates the presence of excess protein in the urine. This can encompass a range from mild proteinuria to nephrotic syndrome, characterized by significant protein loss, hypoalbuminemia, edema and hyperlipidemia [4].

Hematuria: Microscopic or macroscopic hematuria, the presence of blood in the urine, is another frequent observation in lupus nephritis. It results from glomerular injury and when it remains persistent, it can lead to considerable renal impairment [5].

Hypertension: Elevated blood pressure is commonly observed in individuals with lupus nephritis and can lead to further kidney damage. Increased blood pressure worsens the glomerular injury caused by the immune complexes.

Renal dysfunction: In severe instances, lupus nephritis can result in a decline in kidney function, presented as increased serum creatinine levels and diminished glomerular filtration rate. This can eventually evolve into chronic kidney disease or ESRD, necessitating renal replacement therapy [6].

Other systemic symptoms: Since lupus nephritis is part of systemic lupus erythematosus, patients may also encounter general systemic symptoms of SLE, such as fatigue, fever, weight loss and skin rashes.

Diagnosis of lupus nephritis

The identification of lupus nephritis necessitates a combination of clinical evaluation, laboratory assessments and kidney biopsy.

Kidney biopsy: A kidney biopsy is the definitive method for diagnosing lupus nephritis and establishing its classification. The biopsy enables the histological assessment of kidney tissue and can reveal the degree of glomerular injury and the type of lupus nephritis which informs treatment choices [7].

Immunosuppressive therapy: The foundation of lupus nephritis management is immunosuppressive therapy aimed at diminishing the inflammatory response. This generally encompasses corticosteroids, like prednisone and supplementary immunosuppressive medications such as cyclophosphamide, mycophenolate mofetil, or azathioprine. These drugs assist in regulating the immune system and avert additional kidney damage [8].

Biologic agents: In recent times, biologic agents like belimumab have been employed as supplementary therapy in lupus nephritis. These medications aid in lowering disease activity through immune system modulation [9].

Angiotensin-converting enzyme inhibitors: Angiotensin- Converting Enzyme Inhibitors (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs) are frequently prescribed to manage proteinuria and hypertension in lupus nephritis. These drugs can slow down kidney disease progression and lessen cardiovascular risk.

Renal replacement therapy: In situations where lupus nephritis advances to end-stage renal disease, dialysis or kidney transplantation might be required [10].

Conclusion

Lupus nephritis is a potentially life-threatening complication of systemic lupus erythematosus, marked by inflammation and damage to the kidneys. Prompt diagnosis and suitable treatment are crucial for preventing renal failure and enhancing patient outcomes. The management of lupus nephritis necessitates a multidisciplinary approach, integrating immunosuppressive therapies, symptom management and meticulous monitoring of renal function. Progress in treatment, especially with biologic therapies, has greatly enhanced the prognosis for numerous patients with lupus nephritis, but ongoing research is essential to refine treatment options and improve outcomes.

References

1. Ludwig CF (1994) 1842--a landmark in nephrology: Carl ludwig's revolutionary concept of renal function. Kidney Int Suppl 46: 1-23.

   [Google scholar], [Indexed]

2. Sahay M, Narayen G, Anuradha (2007) Risk of live kidney donation-indian perspective. J Assoc Physicians India 55: 267-270.

   [Google scholar], [Indexed]

3. Barai S, Gambhir S, Prasad N, Sharma RK, Ora M, et al. (2008) Levels of gfr and protein-induced hyperfiltration in kidney donors: A single-center experience in india. Am J Kidney Dis 51: 407- 414.

   [Crossref], [Google scholar], [Indexed]

4. Barai S, Bandopadhayaya GP, Patel CD, Rathi M, Kumar R, et al. (2005) Do healthy potential kidney donors in india have an average glomerular filtration rate of 81.4 ml/min? Nephron Physiol 101: 21-26.

   [Crossref], [Google scholar], [Indexed]

5. Bakker J, Olree M, Kaatee R, De Lange EE, Moons KG, et al. (1999) Renal volume measurements: Accuracy and repeatability of us compared with that of mr imaging. Radiology 211: 623-8.

   [Crossref], [Google scholar], [Indexed]

6. Okoye IJ, Agwu KK, Idigo FU (2005) Normal sonographic renal length in adult southeast nigerians. Afr J Med Med Sci 34: 129-31.

   [Google scholar], [Indexed]

7. Pruijm M, Ponte B, Ackermann D, Vuistiner P, Paccaud F, et al.  (2013) Heritability, determinants and reference values of renal length: A family-based population study. Eur Radiol 23: 2899-905.

   [Crossref], [Google scholar], [Indexed]

8. Ganesh R, Vasanthi T, Lalitha J, Rajkumar J, Muralinath S (2010) Correlation of renal length with somatic variables in indian children. Indian J Pediatr 77: 326-8.

   [Crossref], [Google scholar], [Indexed]

9. Chitra K, Sebastain A, Manjula VD, Sumadevi VS, Annamma K (2015) Age related changes of gfr in a population of kerala”. Journal of Evidence based Medicine and Healthcare 34: 5226-5231.
10. Emamian SA, Nielsen MB, Pedersen JF (1993) Kidney dimensions at sonography: Correlation with age, sex, and habitus in 655 adult volunteers. AJR Am J Roentgenol 160: 83-6.

    [Crossref], [Google scholar], [Indexed]